Please login to the form below

Not currently logged in
Email:
Password:

obinutuzumab

This page shows the latest obinutuzumab news and features for those working in and with pharma, biotech and healthcare.

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

and preliminary data with Roche’s CD20-tareitng antibody Gazyva (obinutuzumab).

Latest news

  • Imbruvica gains expanded use in Europe Imbruvica gains expanded use in Europe

    drug. . The EC has approved the use of Imbruvica in combination with obinutuzumab (Gazyva, Roche) in adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and in combination with rituximab (Rituxan,

  • AZ’s Calquence threatens Imbruvica with new leukaemia data AZ’s Calquence threatens Imbruvica with new leukaemia data

    Earlier this month AZ reported that Calquence  alone or in combination with Roche’s Gazyva (obinutuzumab) significantly increased the time patients lived without disease progression compared to Gazyva and chlorambucil chemotherapy.

  • Venclexta plus Gazyva approval adds to non-chemo options in CLL Venclexta plus Gazyva approval adds to non-chemo options in CLL

    Joins Imbruvica combo in front line use. Roche has gained FDA approval for Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in a new front line use in patients with previously untreated

  • Roche files Venclexta plus Gazyva in CLL Roche files Venclexta plus Gazyva in CLL

    Chemo-free combo assessed via FDA's Real-Time review. Roche has filed Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) with the FDA for a new front line use in patients

  • Imbruvica and Gazyvo approved in first non-chemo CLL use Imbruvica and Gazyvo approved in first non-chemo CLL use

    The approval is also good news for Roche and its drug Gazyvo (obinutuzumab) which the company is trying to prove as superior next-generation version of MabThera/Rituxan (rituximab) which is ... Imbruvica as a single agent – and now as a combination

More from news
Approximately 11 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics